Your browser doesn't support javascript.
loading
Development of PI3Kγ selective inhibitors: the strategies and application.
Gu, Dong-Yan; Zhang, Meng-Meng; Li, Jia; Zhou, Yu-Bo; Sheng, Rong.
Afiliação
  • Gu DY; College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
  • Zhang MM; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Li J; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Zhou YB; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Sheng R; College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China. shengr@zju.edu.cn.
Acta Pharmacol Sin ; 45(2): 238-247, 2024 Feb.
Article em En | MEDLINE | ID: mdl-37803138
The γ isoform of Class I PI3Ks (PI3Kγ) is primarily found in leukocytes and is essential for the function of myeloid cells, as it regulates the migration, differentiation, and activation of myeloid-lineage immune cells. Thus, PI3Kγ has been identified as a promising drug target for the treatment of inflammation, autoimmune disease, and immuno-oncology. Due to the high incidence of serious adverse events (AEs) associated with PI3K inhibitors, in the development of PI3Kγ inhibitors, isoform selectivity was deemed crucial. In this review, an overview of the development of PI3Kγ selective inhibitors in the past years is provided. The isoform selectivity of related drugs was achieved by different strategies, including inducing a specificity pocket by a propeller-shape structure, targeting steric differences in the solvent channel, and modulating the conformation of the Asp-Phe-Gly DFG motif, which have been demonstrated feasible by several successful cases. The insights in this manuscript may provide a potential direction for rational drug design and accelerate the discovery of PI3Kγ selective inhibitors.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Fosfatidilinositol 3-Quinases Limite: Humans Idioma: En Revista: Acta Pharmacol Sin Assunto da revista: FARMACOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Fosfatidilinositol 3-Quinases Limite: Humans Idioma: En Revista: Acta Pharmacol Sin Assunto da revista: FARMACOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China